Shenzhen YHLO Biotech Co., Ltd. (688575.SS)
CNY 14.9
(0.4%)
CNY 14.9
(0.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 537.36 Million CNY | -70.42% |
| 2022 | 1.33 Billion CNY | 299.43% |
| 2021 | 344.74 Million CNY | 5.45% |
| 2020 | 324.17 Million CNY | 65.66% |
| 2019 | 183.12 Million CNY | 130.68% |
| 2018 | 76.03 Million CNY | 261.22% |
| 2017 | 24.52 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 171.33 Million CNY | 57.54% |
| 2024 Q1 | 68.73 Million CNY | -12.71% |
| 2024 Q3 | 52.09 Million CNY | -70.79% |
| 2023 Q2 | 60.83 Million CNY | -42.98% |
| 2023 FY | - CNY | -70.42% |
| 2023 Q3 | 179.21 Million CNY | 194.6% |
| 2023 Q1 | 106.69 Million CNY | -56.07% |
| 2023 Q4 | 89.07 Million CNY | -50.3% |
| 2022 Q2 | 140.93 Million CNY | -76.69% |
| 2022 FY | - CNY | 299.43% |
| 2022 Q4 | 242.88 Million CNY | -17.07% |
| 2022 Q1 | 604.5 Million CNY | 839.46% |
| 2022 Q3 | 292.86 Million CNY | 107.8% |
| 2021 Q1 | 50.92 Million CNY | -30.43% |
| 2021 FY | - CNY | 5.45% |
| 2021 Q4 | 64.34 Million CNY | -18.36% |
| 2021 Q2 | 63.54 Million CNY | 24.77% |
| 2021 Q3 | 78.81 Million CNY | 24.03% |
| 2020 Q2 | 129.69 Million CNY | 3429.3% |
| 2020 Q4 | 73.2 Million CNY | 17.25% |
| 2020 FY | - CNY | 65.66% |
| 2020 Q3 | 62.42 Million CNY | -51.87% |
| 2020 Q1 | 3.67 Million CNY | 0.0% |
| 2019 FY | - CNY | 130.68% |
| 2018 FY | - CNY | 261.22% |
| 2017 FY | - CNY | 0.0% |